GTC Biotherapeutics (fka GTCB)

[keitern]

From the CC transcript (thanks again Dew)
>>Our objective for the recombinant alpha 1 antitrypsin program is to initially establish an intravenous product for the prophylactic treatment of patients with a genetic deficiency of alpha 1 antitrypsin. Remember that we established high levels of production of this difficult to express protein at 20 grams per liter of milk. Hereditary-deficiency patients who are not treated prophylactically suffer from a build-up of elastase in the lung that may lead to emphysema or other respiratory conditions. We believe we have identified appropriate techniques to extend the half-life of our alpha 1 antitrypsin product to enable it to be dosed in a similar manner as plasma-derived products. Once we establish an appropriate formulation of our alpha 1 antitrypsin product, we can complete our pre clinical development over the next 12 months.

We recently met with a representative of the Alpha 1 Foundation where they described the very real concerns their members have with managing their treatment with plasma-derived products. They encouraged us in our efforts to develop a robust supply of our recombinant product to help these patients maintain as much lung function as possible.<<

The language in the above paragraphs leads me to believe it is a matter of "when" this gets approved, not "if", however I would appreciate some counterpoint on this.